ZNF385 Inhibitors
Chemical inhibitors of ZNF385 can impact its activity through various mechanisms, primarily by modulating the kinase pathways that lead to its activation or inactivation. Forskolin, for instance, engages directly with adenylyl cyclase to elevate cAMP levels, which activates protein kinase A (PKA). Active PKA can phosphorylate ZNF385, thus promoting its function as a transcription factor. Similarly, Sildenafil and Zaprinast inhibit phosphodiesterase type 5 (PDE5), leading to increased levels of cGMP and the subsequent activation of protein kinase G (PKG). PKG can phosphorylate proteins that interact with ZNF385, which may result in its activation. Conversely, certain kinase inhibitors operate by preventing the phosphorylation of ZNF385 that would lead to its inactivation. SB 203580 serves this purpose by inhibiting p38 MAPK, a kinase known to negatively regulate ZNF385. LY294002 inhibits PI3K, preventing it from phosphorylating downstream targets that contribute to ZNF385 inactivation, thereby fostering an environment conducive to ZNF385's active state.
Additional chemicals that influence the activity of ZNF385 include Genistein, which by inhibiting tyrosine kinases, prevents negative regulation of ZNF385, allowing it to remain active. In the same vein, PD98059 and U0126, both MEK inhibitors, reduce the phosphorylation and activation of ERK, which could otherwise lead to ZNF385's inactivation. By blocking MEK, these inhibitors maintain ZNF385 in an active form. SP600125, a JNK inhibitor, operates on a similar principle; it halts the inactivation of ZNF385 by preventing JNK from phosphorylating its substrates. Y-27632, a ROCK inhibitor, contributes to ZNF385's activity by obstructing the Rho/ROCK pathway, which is implicated in phosphorylating proteins that may inhibit ZNF385. Lastly, Anisomycin, though a protein synthesis inhibitor, can activate stress-activated protein kinases such as JNK, which can indirectly lead to the phosphorylation and activation of ZNF385, particularly under stress conditions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate (EGCG) can inhibit the activity of DNA methyltransferases, which may lead to decreased methylation of the ZNF385 gene and adjacent areas, potentially resulting in the activation of ZNF385 through a more open chromatin state and increased transcription factor accessibility. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can indirectly lead to the activation of ZNF385 by inhibiting negative regulatory kinases, thereby allowing ZNF385 to remain in an active state. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor that can enhance the activation of ZNF385 by inhibiting p38 MAPK, a kinase that may negatively regulate ZNF385 through phosphorylation and consequent inactivation. By inhibiting this kinase, SB 203580 can help maintain ZNF385 in an active state. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can increase the activity of ZNF385 by preventing PI3K from phosphorylating downstream targets that may lead to the inactivation of ZNF385. By inhibiting PI3K, LY294002 promotes a cellular environment that favors ZNF385 activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK. By inhibiting MEK, PD98059 can prevent the phosphorylation and activation of ERK, which may otherwise phosphorylate ZNF385 leading to its inactivation. Thus, PD98059 can support the active state of ZNF385. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which can phosphorylate specific substrates leading to the inactivation of transcription factors like ZNF385. By inhibiting JNK, SP600125 can prevent the inactivation of ZNF385, thereby supporting its active state. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor similar to PD98059 and can increase the activity of ZNF385 by inhibiting MEK, thereby reducing ERK phosphorylation and activity, which may lead to the inactivation of ZNF385. By preventing MEK from activating ERK, U0126 supports the active state of ZNF385. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast functions similarly to Sildenafil by inhibiting PDE5 and increasing cGMP levels, which can lead to the activation of PKG. PKG may then phosphorylate and activate ZNF385 indirectly. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that can increase the activity of ZNF385 by inhibiting the Rho/ROCK pathway, which is known to be involved in cytoskeletal rearrangements. By inhibiting ROCK, Y-27632 can prevent phosphorylation of downstream targets that could inhibit the activity of ZNF385, thus promoting its active state. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can activate stress-activated protein kinases (SAPKs) like JNK, which, paradoxically, might also phosphorylate substrates that can interact with and activate ZNF385, leading to its functional activation in a stress response context. | ||||||